[18F]FLOR PET/CT Imaging for Prostate Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a special scan that uses a radioactive dye to detect cancer spread in patients with metastatic prostate cancer. The dye helps highlight cancer cells during the scan, making it easier for doctors to see where the cancer is located.
Will I have to stop taking my current medications?
The trial requires that at least 2 weeks have passed since your last anti-cancer treatment before the imaging day. It doesn't specify about other medications, so it's best to discuss with the study team.
What data supports the effectiveness of the drug [18F]FLOR (FC303) Injection for prostate cancer?
Is [18F]FLOR PET/CT Imaging for Prostate Cancer safe for humans?
Flotufolastat F 18, a similar imaging agent, was approved in the USA in May 2023 for prostate cancer imaging, indicating it has been evaluated for safety in humans. While specific safety data for [18F]FLOR is not detailed, the approval of similar agents suggests a level of safety in human use.678910
How is [18F]FLOR PET/CT Imaging different from other treatments for prostate cancer?
[18F]FLOR PET/CT Imaging is unique because it uses a specific radiotracer for PET/CT scans to detect prostate cancer, potentially offering more precise imaging compared to traditional methods. This can help in identifying the cancer's location and extent more accurately, which is crucial for planning effective treatment.358911
Research Team
Steven Rowe, M.D., Ph.D.
Principal Investigator
Johns Hopkins University
Eligibility Criteria
This trial is for men over 18 with confirmed adenocarcinoma of the prostate who have signs of recurring or spreading cancer. They must not have had cancer treatment in the last 2 weeks and should be able to follow study procedures. Men who've recently received radioisotopes or have conditions that may skew results can't participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo [18F]FLOR (FC303) PET/CT imaging to assess the presence of metastatic prostate cancer
Follow-up
Participants are monitored for safety and effectiveness after imaging
Treatment Details
Interventions
- [18F]FLOR (FC303) Injection
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead Sponsor
FutureChem
Industry Sponsor